Democrats will have to figure out how to keep Trump a badie, but shall never point any finger their way, to look at the mirror, to admit anything, never!

Exclusive news, data and analytics for financial market professionals World Business Markets Sustainability Legal Breakingviews Technology Investigations More My News Feedback Trump executive order demands pharma industry price cuts By Steve Holland, Michael Erman and Patrick Wingrove May 12, 20253:30 PM PDTUpdated 8 min ago Summary Companies Trump tells drugmakers to cut prices to 'most favored nation' pricing Pharmaceutical shares rise as analysts question how it can be implemented Order calls for FTC to look for anti-competitive pricing WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement. The order gives drugmakers price targets in the next 30 days, and will take further action to lower prices if those companies do not make "significant progress" toward those goals. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Advertisement · Scroll to continue Report This Ad The order was not as bad as feared, investors, analysts and drug pricing experts said, and they questioned how it would be implemented. Shares of drugmakers, which had been down on the threat of "most favored nation" pricing, recovered and rose on Monday. Trump told a press conference that the government would impose tariffs if the prices in the U.S. did not match those in other countries and said he was seeking cuts of between 59% and 90%. "Everybody should equalize. Everybody should pay the same price," Trump said. The United States pays the highest prices for prescription drugs, often nearly three times more than other developed nations. Trump tried in his first term to bring the U.S. in line with other countries but was blocked by the courts. Advertisement · Scroll to continue Report This Ad Trump's drug pricing proposal comes as the president has sought to fulfill a campaign promise of tackling inflation and lowering prices for a host of everyday items for Americans, from eggs to gas for their cars. Trump said his order on drug prices was partly a result of a conversation with an unnamed friend who told the president he got a weight-loss injection for $88 in London and that the same medicine in the U.S. cost $1,300. If drugmakers do not meet the government’s expectations, it will use rulemaking to bring drug prices to international levels and consider a range of other measures, including importing medicines from other developed nations and implementing export restrictions, a copy of the order showed. Trump's order directs the government to consider facilitating direct-to-consumer purchasing programs that would sell drugs at the prices other countries pay. Trade groups representing biotech and pharmaceutical companies decried the move. "Importing foreign prices from socialist countries would be a bad deal for American patients and workers. It would mean less treatments and cures and would jeopardize the hundreds of billions our member companies are planning to invest in America," Stephen Ubl, CEO of industry trade group PhRMA, said in a statement. Ubl said the real reasons for high drug prices are "foreign countries not paying their fair share and middlemen driving up prices for U.S. patients." Item 1 of 3 U.S. President Donald Trump holds a signed executive order, as he attends a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025. REUTERS/Nathan Howard [1/3]U.S. President Donald Trump holds a signed executive order, as he attends a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025. REUTERS/Nathan Howard Purchase Licensing Rights, opens new tab The order also directs the U.S. Federal Trade Commission to consider aggressive enforcement against what the government calls anti-competitive practices by drugmakers. During a briefing, a White House official pointed to tactics the pharmaceutical industry uses to prevent competition, such as deals with generic companies to delay market entry of cheaper alternatives, as enforcement targets. 'A FLOOD OF LITIGATION' The executive order is likely to face legal challenges, particularly for exceeding limits set by U.S. law, including on imports of drugs from abroad, said health policy lawyer Paul Kim. "The order's suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows." Such challenges are likely months away, and will come after the Trump administration takes more concrete action to force companies to lower prices instead of the “scattershot threats” included in the executive order, according to Lawrence Gostin, a professor of health law at Georgetown Law. “At the point when there are actual consequences and we know what they are, and when companies feel that they have to lower the price of their drugs, at that point we're going to have a flood of litigation,” Gostin said. The Federal Trade Commission has a long history of antitrust enforcement actions against drugmakers and other healthcare companies. Trump last month ordered the FTC to coordinate with other federal agencies to hold listening sessions on anticompetitive practices in the drug industry. On Monday, Trump was expected to ask the FTC to consider taking enforcement action, sources said. "President Donald Trump campaigned on lowering drug costs and today he’s doing just that. Americans are tired of getting ripped off. The Federal Trade Commission will be a proud partner in this new effort," said FTC spokesperson Joe Simonson. Shares of major drugmakers, after initially falling during premarket trading, rallied on Monday along with the broader market. Shares of Merck & Co (MRK.N), opens new tab closed up 5.8%, while Pfizer (PFE.N), opens new tab gained 3.6% and Gilead Sciences (GILD.O), opens new tab finished up 7.1%. Eli Lilly (LLY.N), opens new tab, the world's largest drugmaker by market value, rose 2.9%. Analysts said the order did not contain the kinds of detailed plans for price cuts that would raise concerns. "Implementing something like this is pretty challenging. He tried to do this before and it was stopped by the courts," said Evan Seigerman, analyst at BMO Capital Markets. Trump's order directs the government to consider facilitating direct-to-consumer purchasing programs that would sell drugs at the prices other countries pay. It also orders the Secretary of Commerce and other agency heads to review and consider actions regarding the export of pharmaceutical drugs or ingredients that may contribute to price differences. The Commerce Department did not immediately respond to a request for comment. Reporting by Patrick Wingrove and Michael Erman in New York; Steve Holland, Susan Heavey and Jarrett Renshaw in Washington D.C., Additional reporting by Jody Godoy, Karen Freifeld and Dietrich Knauth in New York and Maggie Fick in London; Editing by Caroline Humer, Mark Porter, Alistair Bell and Bill Berkrot

Dark Hawthorn Story below!

People you don't want in your life, especially in marriage.

When the Democrats steal from the republican's they become the PROUD BABIES! They want to play with us in their haunted doll house! Are you ready!

I hope Trump writes a book about this day.

President Trump just broke every kind of human record: Time now for the word on Wall Street. Fox Business US-China trade deal is 'a really big break' for markets, expert says President Donald Trump said Monday that his administration reached an agreement with China to temporarily lower tariffs while the two sides negotiate a final agreement, which the president says will open the Chinese market for U.S. firms. "The biggest thing that we're discussing is the opening up China, and they've agreed to do that, but it's going to take a while to paper it, you know, that's not the easiest thing to paper," Trump said, noting that it will take time to finalize a formal version of the agreement. Connection for Seniors Singles Ad Connection for Seniors Singles WingTalks Join Now call to action icon "I think it would be fantastic for our businesses if we could go in and compete and compete with China," Trump said. "It would be a lot of jobs for China, it would be I think at a time when they can frankly use the jobs, and that's what we're talking about." He went on to explain that his administration's push for more market access in China for U.S. businesses is a means of resetting the balance of trade between the two countries, including through the removal of non-tariff barriers to trade. US, CHINA ANNOUNCE REDUCED TARIFFS FOR 90 DAYS AFTER TRADE TALKS President Trump said the most important part of the deal is China opening access to U.S. companies. Getty Images President Trump said the most important part of the deal is China opening access to U.S. companies. Getty Images © Chris Kleponis/CNP/Bloomberg via Getty Images "We opened up our country to China, they have very few restrictions, and they didn't open their country to us. Never made sense to me. It's not fair. And they've agreed to open China – fully open China. And I think it's going to be fantastic for China, I think it's going to be fantastic for us, and I think it's going to be great for unification and peace." READ ON THE FOX BUSINESS APP "China also will suspend and remove all of its non-monetary barriers. They've agreed to do that… they're very numerous," he added. TRUMP USING POWER OF AMERICAN ECONOMY TO OPEN CHINA TO US EXPORTERS: LUTNICK Tariffs are taxes on imported goods that are paid by U.S. importers, who typically pass higher costs on to consumers through higher prices. Getty Images Tariffs are taxes on imported goods that are paid by U.S. importers, who typically pass higher costs on to consumers through higher prices. Getty Images © Photographer: Michael Nagle/Bloomberg via Getty Images The president said that the "reciprocal" tariffs that were unveiled at the White House in so-called Liberation Day festivities on April 2, will be dropped from 125% to 10%, lowering the overall tariff on Chinese imports from 145% to 30% for a 90-day period, while China reduces its tariffs from 125% to 10%. Ozempic Injection Cost In Canada - Save Extra 10% with FIRST10 Ad Ozempic Injection Cost In Canada - Save Extra 10% with FIRST10 pharmagiant.com Learn more call to action icon "Yesterday, we achieved a total reset with China. After productive talks in Geneva, both sides now agreed to reduce the tariffs imposed after April 2nd to 10% for 90 days as negotiators continue on the largest structural issues," Trump said. "That doesn't include the tariffs that are already on that are our tariffs, and it doesn't include tariffs on cars, steel, aluminum, things such as that, or tariffs that may be imposed on pharmaceuticals because we want to bring the pharmaceutical businesses back to the United States," he said. TRUMP SAYS TARIFFS ARE INCENTIVIZING US INVESTMENT, HURTING CHINA China's President Xi Jinping and President Donald Trump are working on a final trade agreement. Getty Images China's President Xi Jinping and President Donald Trump are working on a final trade agreement. Getty Images © Getty Images Trump went on to characterize the trade negotiations as being "very friendly" and touted the relationship with China, saying a deal will help boost the country's economy. "The relationship is very good. We're not looking to hurt China; China is being hurt very badly. They were closing up factories, they were having a lot of unrest, and they were very happy to be able to do something with us," Trump said. MONOPOLY - Enjoy MONOPOLY Free - Play MONOPOLY Free Now Ad MONOPOLY - Enjoy MONOPOLY Free - Play MONOPOLY Free Now appcracy.com Learn more call to action icon The president also referenced China's failure to comply with the "phase one" trade deal he reached with the Chinese government during his first term in office. Treasury Secretary Scott Bessent said late last month in an appearance on FOX Business Network's "Kudlow" that the U.S. will "have to take into account that they didn't adhere to the phase one deal."